Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
In this review the clinical pharmacology of HIV protease inhibitors, a new class of antiretroviral drugs, is discussed. After considering HIV protease function and structure, the development of inhibitors of HIV protease is presented. Three protease inhibitors are reviewed in more detail: saquinavir, indinavir, and ritonavir. Clinical trial results with these agents are evaluated. Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed.
Hoetelmans
R M
RM
Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
Meenhorst
P L
PL
Mulder
J W
JW
Burger
D M
DM
Koks
C H
CH
Beijnen
J H
JH
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D002986:Clinical Trials as Topic; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019438:Ritonavir / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019258:Saquinavir / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D019469:Indinavir; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir